KEYNOTE-585: Randomized, phase 3 study of chemotherapy + pembrolizumab vs chemotherapy + placebo as neoadjuvant/adjuvant treatment for patients with gastric or gastroesophageal junction (G/GEJ) cancer Meeting Abstract
| Authors: | Bang, Y. J.; Van Cutsem, E.; Fuchs, C.; Ohtsu, A.; Tabernero, J.; Ilson, D.; Hyung, W. J.; Strong, V.; Goetze, T.; Yoshikawa, T.; Tang, L.; Sun, L.; Hasan, A.; Koshiji, M.; Shitara, K. |
| Abstract Title: | KEYNOTE-585: Randomized, phase 3 study of chemotherapy + pembrolizumab vs chemotherapy + placebo as neoadjuvant/adjuvant treatment for patients with gastric or gastroesophageal junction (G/GEJ) cancer |
| Meeting Title: | 32nd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2017) |
| Journal Title: | Journal for ImmunoTherapy of Cancer |
| Volume: | 5 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2017 Nov 8-12 |
| Meeting Location: | National Harbor, MD |
| ISSN: | 2051-1426 |
| Publisher: | Biomed Central Ltd |
| Date Published: | 2017-11-07 |
| Start Page: | 87 |
| Language: | English |
| DOI: | 10.1186/s40425-017-0288-4 |
| PROVIDER: | manual |
| Notes: | Meeting Abstract: P218 |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work